SCHEMBL7183640

SCHEMBL7183640

COc1cc(OC)c(C(=O)Pc2c(OCCC(C)C)cc(OCCC(C)C)cc2OCCC(C)C)c(OC)c1.[LiH]

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
CYP3A4 P08684 1/20 0.37
EPHX2 P34913 1/20 0.36
HTT P42858 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7184556 0.91 HTT (0.42) MAPK1KDM4EALDH1A1GAAPKM
SCHEMBL7185372 0.86 CYP3A4 (0.39) MAPK1KDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL7182404 0.86 CYP3A4 (0.39) MAPK1KDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL7181351 0.85 HDAC3 (0.41) MAPK1KDM4EGAAKMT2ASMN1; SMN2
SCHEMBL7185228 0.85 USP2 (0.38) MAPK1KMT2ASMN1; SMN2USP2CYP3A4
SCHEMBL7187747 0.85 MAPK1 (0.41) MAPK1KDM4EALDH1A1GAAKMT2A
SCHEMBL7186646 0.84 MAPK1 (0.46) MAPK1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL7179902 0.84 HTT (0.39) MAPK1KDM4EALDH1A1SMN1; SMN2EPHX2
SCHEMBL7188509 0.84 PLA2G2A (0.42) KDM4ECYP3A4
SCHEMBL7177745 0.83 APP (0.37) MAPK1KDM4EKMT2ASMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPK1 1801/4885KDM4E 3226/4885ALDH1A1 3416/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPK1 2710/4885KDM4E 2651/4885ALDH1A1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.